Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Latest in mRCC from ESMO 2022

Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Ou...

Latest in mRCC from ESMO 2022 ( Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Oudard )

Ideal duration of androgen deprivation therapy with post-operative radiotherapy ...

Prof Chris Parker - Institute of Cancer Research, Sutton, UK

Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

Dr Silvia Novello - University of Turin, Turin, Italy

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )

EGFR mutations in NSCLC - from biomarker to treatment selections in second line

Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo

EGFR mutations in NSCLC - from biomarker to treatment selections in second line ( Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo )

ESMO 2022: Renal roundup

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ESMO 2022: Renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Fruquintinib provides improvement in overall survival for refractory mCRC

Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA

$Fruquintinib provides improvement in overall survival for refractory mCRC ( Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA )$

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-smal...

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or ...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Emerging systemic therapies in rare urothelial cancer variants

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

Emerging systemic therapies in rare urothelial cancer variants ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

Lenvatinib plus pembro for aRCC - update on the CLEAR study ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim ...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast can...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

More from ecancer